Biel

Researchers are investigating the best approach to treat low-risk patients with isolated subsegmental pulmonary embolism SSPE, a type of blood clot in small lung arteries. The study aims to determine whether monitoring patients without anticoagulation is as safe and effective as giving anticoagulant medication. This is important because many patients currently receive anticoagulants that carry a risk of bleeding, but it is unclear if all patients with isolated SSPE need this treatment. Patients in the trial are randomly assigned to one of two groups. One group receives the anticoagulant drug rivaroxaban, starting with 15 mg twice daily for 21 days, then 20 mg once daily for a total of 90 days. The other group receives a placebo matching the same schedule. The trial compares clinical surveillance without anticoagulation to anticoagulation treatment to assess safety and effectiveness. Participants will be followed for 90 days after randomization to monitor for recurrent venous thromboembolism, significant bleeding events, and overall survival. Researchers will track these outcomes through clinical assessments and safety monitoring. This study is designed to evaluate if careful monitoring alone is a safe alternative to anticoagulation in selected patients with isolated SSPE, potentially reducing bleeding risks from treatment.

Researchers are conducting the SwissPrEPared Study to observe and follow individuals in Switzerland who request pre-exposure prophylaxis PrEP prescriptions. The study aims to gather long-term data on PrEP use, including how common it is, the types of PrEP regimens used, and the occurrence of sexually transmitted infections STIs among this population. It also seeks to assess sexual health and well-being using a specialized questionnaire designed for this program. Participants include individuals aged 16 and older who request PrEP at participating centers and are HIV negative. The study involves ongoing recruitment and observation over a period of 3 years within the SwissPrEPared program. There are no interventional treatments instead, researchers collect data on participants PrEP usage patterns, drug supply methods, adherence, and side effects. Participants will be monitored through questionnaires and medical assessments to track the prevalence and incidence of HIV and other STIs such as syphilis, hepatitis B and C, gonorrhoea, chlamydia, and mycoplasma genitalium. Researchers will also evaluate adherence to PrEP and the program itself over a 10-year period. The study includes regular data collection on these outcomes to better understand the sexual health of individuals using PrEP in Switzerland.